SynthesisFrontiers in oncology2026
Body mass index and prostate cancer incidence: a comprehensive systematic review.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate cancer, the second leading cause of cancer-related mortality among men in the U.S., is projected to cause over 36,000 deaths in 2025. This systematic literature review investigates the association between body mass index (BMI) and prostate cancer incidence, evaluating evidence from 2004 to October 2025. Methods: A comprehensive search of PubMed using the keywords "BMI" and "prostate cancer" and "screening" identified 60 articles, from which 24 relevant studies were selected for direct analysis. Results: While some studies show a positive correlation between higher BMI and increased risk of prostate cancer, others report no significant association or an inverse relationship. Thus, the overall evidence supports a neutral relationship between BMI and prostate cancer risk. Discussion: The review explores potential biological mechanisms linking BMI to prostate cancer, including metabolic dysregulation, hormonal changes, and genetic factors. Additionally, it examines how factors such as age, race/ethnicity, and socioeconomic status may modify this relationship. The review highlights that although a higher BMI is generally associated with increased prostate cancer risk and poorer outcomes, the evidence is inconsistent. Key limitations include high variability in study designs and outcome measures, short follow-up periods as well as studies predominantly from Western populations. These inconsistencies underscore the need for further research to clarify the relationship and improve targeted interventions to mitigate prostate cancer's impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.